Clinical Trial Update: Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors [Phase 2]

View source ↗

Summary

Phase 2 clinical trial examining a combination of ruxolitinib and tyrosine kinase inhibitors in chronic myeloid leukemia with reports of treatment-free remissio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Myeloid Leukemia Chronic Phase

Drugs mentioned

• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: H. Lee Moffitt Cancer Center and Research Institute | Conditions: Chronic Phase Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase | Phase 2 | Status: ACTIVE_NOT_RECRUITING